Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis
- PMID: 8904518
- DOI: 10.1046/j.1365-2362.1996.114256.x
Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis
Abstract
Non-insulin-dependent diabetes mellitus is frequently associated with premature atherosclerosis. Abnormalities in lipid and lipoprotein metabolism contribute to the increased risk of coronary heart disease. One of the most common lipid abnormalities in non-insulin-dependent diabetes mellitus is hypertriglyceridaemia. In the present paper, the authors review the metabolism of triglyceride-rich lipoproteins, with special emphasis on the post-prandial state. Several studies have demonstrated that levels of atherogenic post-prandial lipoproteins are increased in patients with non-insulin-dependent diabetes mellitus. An increased supply of glucose and free fatty acids contributes to overproduction of very low-density lipoproteins, increasing the burden of triglyceride-rich lipoproteins on the common lipolytic pathway at the level of lipoprotein lipase. Low lipoprotein lipase activity and increased amounts of lipolysis-inhibiting free fatty acids further impair lipolysis of post-prandial lipoproteins. The clearance of atherogenic remnants is also delayed in non-insulin-dependent diabetes mellitus. There is evidence that a relative hepatic removal defect exists, secondary to impaired remnant-receptor interaction and increased competition with very low density lipoprotein remnants. Correction of the increased post-prandial lipaemia in non-insulin-dependent diabetes mellitus is advisable, as it may contribute to attenuation of the risk on premature atherosclerosis. When dietary measures and hypoglycaemic agents have failed to achieve acceptable lipid levels, lipid-lowering drugs should be advised. Fibric acids and hydroxymethyl-glutaryl coenzyme A (HMG CoA) reductase inhibitors are the drugs of choice.
Similar articles
-
Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment.Eur J Clin Invest. 1997 Jan;27(1):55-63. doi: 10.1046/j.1365-2362.1997.790630.x. Eur J Clin Invest. 1997. PMID: 9041378
-
Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus.Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2397-402. doi: 10.1161/01.ATV.0000146267.71816.30. Epub 2004 Sep 30. Arterioscler Thromb Vasc Biol. 2004. PMID: 15458975
-
[Insulin and the metabolism of lipoproteins].Ann Endocrinol (Paris). 1983 Jan-Mar;44(1):77-81. Ann Endocrinol (Paris). 1983. PMID: 6347030 Review. French.
-
[Diabetic dyslipidaemia and the atherosclerosis].Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Orv Hetil. 2016. PMID: 27133274 Review. Hungarian.
-
Diabetic dyslipidemia.Am J Cardiol. 1998 Dec 17;82(12A):67U-73U; discussion 85U-86U. doi: 10.1016/s0002-9149(98)00848-0. Am J Cardiol. 1998. PMID: 9915665 Review.
Cited by
-
Comparison of diets high in monounsaturated versus polyunsaturated fatty acid on postprandial lipoproteins in diabetes.Ir J Med Sci. 2005 Jan-Mar;174(1):8-20. doi: 10.1007/BF03168513. Ir J Med Sci. 2005. PMID: 15868884 Clinical Trial.
-
Glycemic index of dietary formula may not be predictive of postprandial endothelial inflammation: a double-blinded, randomized, crossover study in non-diabetic subjects.Nutr Res Pract. 2013 Aug;7(4):302-8. doi: 10.4162/nrp.2013.7.4.302. Epub 2013 Aug 7. Nutr Res Pract. 2013. PMID: 23964318 Free PMC article.
-
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.Diabetologia. 2006 Sep;49(9):2049-57. doi: 10.1007/s00125-006-0340-2. Epub 2006 Jul 1. Diabetologia. 2006. PMID: 16816950 Clinical Trial.
-
Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.Drugs. 2005;65(1):31-74. doi: 10.2165/00003495-200565010-00003. Drugs. 2005. PMID: 15610050 Review.
-
Diabetic dyslipidaemia: current treatment recommendations.Drugs. 2000 May;59(5):1101-11. doi: 10.2165/00003495-200059050-00006. Drugs. 2000. PMID: 10852642 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical